Header Logo

Connection

Alan Schneyer to Cell Line

This is a "connection" page, showing publications Alan Schneyer has written about Cell Line.
Connection Strength

0.308
  1. Andrzejewski D, Brown ML, Ungerleider N, Burnside A, Schneyer AL. Activins A and B Regulate Fate-Determining Gene Expression in Islet Cell Lines and Islet Cells From Male Mice. Endocrinology. 2015 Jul; 156(7):2440-50.
    View in: PubMed
    Score: 0.088
  2. del Re E, Sidis Y, Fabrizio DA, Lin HY, Schneyer A. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J Biol Chem. 2004 Dec 17; 279(51):53126-35.
    View in: PubMed
    Score: 0.042
  3. Schneyer AL, Wang Q, Sidis Y, Sluss PM. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab. 2004 Oct; 89(10):5067-75.
    View in: PubMed
    Score: 0.042
  4. Schneyer A, Schoen A, Quigg A, Sidis Y. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology. 2003 May; 144(5):1671-4.
    View in: PubMed
    Score: 0.038
  5. Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology. 2002 May; 143(5):1613-24.
    View in: PubMed
    Score: 0.036
  6. Schneyer AL, Sluss PM, Whitcomb RW, Martin KA, Sprengel R, Crowley WF. Precursors of alpha-inhibin modulate follicle-stimulating hormone receptor binding and biological activity. Endocrinology. 1991 Oct; 129(4):1987-99.
    View in: PubMed
    Score: 0.017
  7. Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem. 2008 Nov 21; 283(47):32831-8.
    View in: PubMed
    Score: 0.014
  8. Sidis Y, Schneyer AL, Keutmann HT. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology. 2005 Jan; 146(1):130-6.
    View in: PubMed
    Score: 0.011
  9. del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem. 2004 May 21; 279(21):22765-72.
    View in: PubMed
    Score: 0.010
  10. Wang QF, Khoury RH, Smith PC, McConnell DS, Padmanahban V, Midgley AR, Schneyer AL, Crowley WF, Sluss PM. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab. 1996 Apr; 81(4):1434-41.
    View in: PubMed
    Score: 0.006
  11. Whitcomb RW, Schneyer AL, Roser JF, Hughes JP. Circulating antagonist of luteinizing hormone in association with infertility in stallions. Endocrinology. 1991 May; 128(5):2497-502.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.